Aurobindo Pharma on 17 August announced that it will launch a tablet to treat HIV in low-to-middle-income countries.

Headquartered in Hyderabad, Aurobindo Pharma manufactures a wide range of generic pharmaceuticals, active pharmaceutical ingredients, and branded speciality pharmaceuticals globally in over 150 countries.

The pharmaceutical giant will bring in a tablet under a voluntary license from Viv Healthcare. The medicine, pLAD, will be a mix of dolutegravir, abacavir, and lamivudine. According to the pharma giant, this combination helps reduce the amount of virus in the body, boosts the immune system, and slows the progression of HIV to AIDS.

Aurobindo plans to use the drug to treat children living with HIV aged at least 3 months and weighing 6 kgs to 25 kgs.

The company plans to sell the pLAD in 123 low-to-middle-income countries, including India.

pLAD is considered an important dosage by the World Health Organisation for kids who are living under HIV; the generic approval will help supply affordable HIV medicine.

K Nithyananda Reddy, Vice-Chairman and Managing Director, said, “We are extremely glad that with this approval, more than a million children could benefit from this product, helping to increase the treatment coverage of children in 123 countries.”

On 16 August, Aurobindo Pharma’s wholly-owned subsidiary received USFDA approval for an Icatibant injection to treat hereditary angioedema. This genetic disorder causes swelling in various body parts, including the skin, airways, and digestive tract.

At 10:50 am, the shares of Aurobindo Pharma were trading at Rs 870.65 or 0.35% below its previous close on NSE.